Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roche, Ocrevus Zunovo
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving
FDA approves Roche’s Ocrevus Zunovo with Halozyme’s Enhanze drug delivery technology
Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis.
Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS
Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.
Roche scores first, with FDA approval of Ocrevus Zunovo for MS
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS),
FDA Approves Subcutaneous Ocrevus for Multiple Sclerosis
Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be available in a few weeks and be priced at parity with Ocrevus IV.
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has its own injectable MS drug, Kesimpta.
Roche's OCREVUS ZUNOVO Gets FDA Approval To Treat Relapsing And Progressive Multiple Sclerosis
Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO
Roche gets USFDA nod for Ocrevus Zunovo for relapsing and progressive multiple sclerosis
Basel: Roche announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics's Enhanze drug delivery technology.
Medpage Today on MSN
2d
Kids With MS May Have Better Outcomes When Started on High-Efficacy Treatment Early
Starting high-efficacy monoclonal antibody therapy during childhood reduced long-term disability in pediatric-onset multiple ...
MM&M
2d
Rx Rundown: MaxCyte, Roche, and more
Kajeet and Avery Telehealth announced a strategic partnership. The FDA has approved Apple’s sleep apnea detection feature.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Alabama mass shooting
To skip Al Smith dinner
CA firefighter held for arson
Ga. suspect's mom indicted
CAH sues for trespassing
Actress Crosby dies at 90
Rejects CNN debate invite
Biden hosts 'Quad' summit
Suns broadcaster dies
CA bill to protect kids online
House repeals emission rules
Released after guilty plea
Feds subpoena Schaeffer
Drug price challenge revived
Pandas leaving for China
Sues pharmacy middlemen
WI high court to decide
144K+ Mavericks recalled
TN abortion law blocked
FDA approves flu vaccine
Boeing defense chief exits
SC 1st execution in 13 years
Hand count approved in GA
Sesame Place suit verdict
J&J unit files for bankruptcy
Beirut strike death toll
Bill to boost security OK'd
ISR strike on Gaza school
In-person voting begins
Related topics
Multiple sclerosis
Food and Drug Administration
Halozyme
Feedback